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Abstract
The objective of the review is to use individual participant data (IPD) meta‐
analysis to explore the effect of mass deworming during pregnancy. We
developed a search strategy and searched the databases till March 2018. We
included individually randomised controlled trials; cluster randomised controlled
trials and quasi randomised studies providing preventive or therapeutic
deworming drugs for soil transmitted helminthiases and schistosomiasis during
pregnancy. All IPD were assessed for completeness, compared to published
reports and entered into a common data spreadsheet. Out of the seven trials
elgible for IPD, we received data from three trials; out of 8,515 potential IPD
participants; data were captured for 5,957 participants. Findings from this IPD
suggest that mass deworming during pregnancy reduces maternal anaemia by
23% (Risk ratio [RR]: 0.77, 95% confidence intreval [CI]: 0.73–0.81; three trials;
5,216 participants; moderate quality evidence). We did not find any evidence of
an effect of mass deworming during pregnancy on any of the other outcomes.
There was no evidence of effect modification; however these findings should be
interpreted with caution due to small sample sizes. The quality of evidence was
rated as moderate for our findings. Our analyses suggest that mass deworming
during pregnancy is associated with reducing anaemia with no evidence of
impact on any other maternal or pregnancy outcomes. Our analyses were limited
by the availability of data for the impact by subgroups and effect modification.
There is also a need to support and promote open data for future IPDs.
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1 | PLAIN LANGUAGE SUMMARY
1.1 | Mass deworming during pregnancy reduces
anaemia but has no effect on other maternal or
pregnancy outcomes
Pregnant women are at particular risk from soil transmitted
helminthiasis (STH) – a group of diseases caused by infection with
four intestinal parasites. Individual‐level data analysis with data from
three studies shows that mass deworming during pregnancy reduces
anaemia but has no effect on any other maternal or pregnancy
outcomes.
1.2 | What is this review about?
Soil transmitted helminthiasis (STH) are a group of diseases caused
by infection with four intestinal parasites (two types of hookworm,
roundworm, and whip worm) which contributed to a total of 4.98
million years lived with disability (YLDs) in 2010. Anaemia is one of
the most common side effects of infection with STH or schistosomes,
due to blood loss in the intestine or urinary tract. Women in low‐
middle‐income countries (LMICs) are especially prone since they may
be pregnant or lactating for as much as half of their reproductive
lives with over 50% of the pregnant women having iron‐deficiency
anaemia.
This review explores whether the effect of mass deworming
during pregnancy varies with individual characteristics (nutritional
status, anaemia), intensity of infection (as assessed by egg count),
infection status (including species of worm), socioeconomic status,
sanitation environment and co‐interventions. The analysis uses
individual patient data (IPD), which means that the original
individual‐level data are obtained for the included studies and
combined into a single data set.
1.3 | What studies are included in this review?
Included studies have to be individually randomised controlled trials;
cluster randomised controlled trials and quasi randomised studies
providing preventive or therapeutic deworming drugs for STH and
schistosomiasis during pregnancy.
From a total of 16 studies on mass deworming during pregnancy
we identified seven trials with 8,515 participants were deemed to be
eligible for individual data analysis. Of these seven trials, we received
data from three trials so that out of 8,515 potential observations
data were captured for 5,957.
1.4 | What are the findings of this review?
Mass deworming during pregnancy reduces maternal anaemia by
nearly one quarter (23%).
There is no effect of mass deworming during pregnancy on any of
other outcomes including Trichiura infection, hookworm infection,
low birthweight (LBW), and preterm birth.
The size of the effect is not affected by Trichiura intensity at
baseline, maternal anaemia at baseline and maternal BMI at baseline.
However these findings should be interpreted with caution due to
small sample sizes. Other potential moderating characteristics could
not be assessed because of lack of data.
The quality of evidence is rated as moderate for our findings.
Further research on maternal baseline worm intensities and birth
outcomes could change our findings.
1.5 | What do the findings of this review mean?
The analyses suggest that mass deworming during pregnancy is
associated with reducing anaemia with no effect on any other
maternal or pregnancy outcomes. The analyses were limited by the
availability of data for the impact by subgroups and effect
modification and thus there is a need to assess mass deworming
for STH and schistosomiasis during pregnancy in large scale
programmatic settings along with an attempt to measure various
individual and environmental factors that could potentially affect its
impact. There is also a need to support and promote open data
for future individual level data analysis.
2 | EXECUTIVE SUMMARY/ABSTRACT
2.1 | Background
Mass deworming is recommended as an effective strategy to prevent
and treat soil transmitted helminthiases (STH) and schistosomiasis.
However there is a great deal of heterogeneity in the existing
evidence and the effectiveness of mass deworming in improving
various maternal and newborn health outcomes is a current source
of debate. Critical appraisal of existing studies suggests that these
studies fail to account for various factors that could modify the
effectiveness of deworming including nutritional status, type of
infection, worm burden and concomitant interventions. Currently, it
is difficult to establish whether mass deworming during pregnancy
has beneficial effects under certain conditions and limited effects
under others.
2.2 | Objectives
The objective of the review is to use individual participant data (IPD)
meta‐analysis to explore whether the effect of mass deworming
during pregnancy varies with individual characteristics (nutritional
status, anaemia), intensity of infection (as assessed by egg count),
infection status (including species of worm), socioeconomic status,
sanitation environment and co‐interventions.
2.3 | Search methods
We developed a search strategy with an information scientist to
search MEDLINE, CINAHL, LILACS, EMBASE, the Cochrane Library,
Internet Documents in Economics Access Service (IDEAS), Google
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Scholar, Web of Sciences, Social Services Abstracts, WHO Global
Health Library, Global Health CABI and CAB Abstracts till March
2018. We also searched grey literature, websites, contacted authors
and screened references of relevant systematic reviews.
2.4 | Selection criteria
We included individually randomised controlled trials; cluster
randomised controlled trials and quasi randomised studies providing
preventive or therapeutic deworming drugs for STH and schistoso-
miasis during pregnancy.
2.5 | Data collection and analysis
We contacted all eligible study authors to invite them to join our
investigators’ collaborative group and share their IPD. We used a
data sharing agreement. All IPD were assessed for completeness,
compared to published reports and entered into a common data
spreadsheet. Risk of bias was assessed using the Cochrane Risk of
Bias tool. Overall quality of the evidence was assessed using the
Grading of Recommendations, Assessment, Development and Eva-
luations (GRADE) methods. This review was registered as a protocol
in the Campbell Collaboration Library.
2.6 | Results
We screened 23,406 records and identified a total of 16 studies on
mass deworming during pregnancy; out of which seven trials with
8,515 participants were deemed to be eligible for IPD. Trial authors
were contacted for all seven trials deemed eligible for the IPD. Out of
the seven trials, we received data from three trials; data from two
trails were lost (trialists were not able to retrieve the data); one
trialist refused to share the data while one could not be contacted
due to severe health conditions. In terms of the number of
participants; out of 8,515 potential IPD participants; data was
captured for 5,957 participants.
Findings from this IPD suggest that mass deworming during
pregnancy reduces maternal anaemia by 23% (Risk ratio (RR): 0.77,
95% confidence intreval (CI): 0.73–0.81; three trials; 5,216 partici-
pants; moderate quality evidence). We did not find any evidence of
an effect of mass deworming during pregnancy on any of other
outcomes including Trichiura infection (RR: 0.69, 95% CI: 0.42–1.13;
two trials; 2,867 participants; moderate quality evidence), hookworm
infection (RR: 0.52, 95% CI: 0.18–1.47; two trials; 2,867 participants;
moderate quality evidence), low birthweight (LBW) (RR: 0.89, 95%
CI: 0.67–1.18; two trials; 2,267 participants; moderate quality
evidence) and preterm birth (RR: 0.69, 95% CI: 0.47–1.03; two trials;
2,707 participants; moderate quality evidence). Due to limited
availability of the data on the pre‐defined effect modifiers, we could
only assess for effect modification by baseline Trichiura infection,
maternal anaemia at baseline and maternal body mass index (BMI) at
baseline. There was no evidence of effect modification by Trichiura
intensity at baseline, maternal anaemia at baseline and maternal BMI
at baseline. However these findings should be interpreted with
caution due to small sample sizes.
The quality of evidence is rated as moderate for our findings.
Further research on maternal baseline worm intensities and birth
outcomes could change our findings.
2.7 | Authors’ conclusions
Our analyses suggest that mass deworming during pregnancy is
associated with reducing anaemia with no impact on any other
maternal or pregnancy outcomes. Our analyses were limited by the
availability of data for the impact by subgroups and effect
modification and thus there is a need to assess mass deworming
for STH and schistosomiasis during pregnancy in large scale
programmatic settings along with an attempt to measure various
individual and environmental factors that could potentially affect its
impact. There is also a need to support and promote open data for
future IPDs.
2.8 | Role of the funder
The Bill and Melinda Gates Foundation had no influence on the
conclusions or publication.
3 | BACKGROUND
3.1 | The problem, condition or issue
Soil transmitted helminthiasis (STH) are a group of diseases caused
by infection with four intestinal parasites: Ascaris lumbricoides
(roundworm), Trichuris trichiura (whip worm), Necator americanus
(hookworm) and Ancylostoma duodenale (hookworm). Schistoso-
miasis is also a parasitic disease caused by blood flukes of the
genus Schistosoma. Six species of schistosomes are responsible for
infection in humans: Schistosoma guineensis, Schistosoma haemato-
bium, Schistosoma intercalatum, Schistosoma japonicum, Schistosoma
mansoni and Schistosoma mekongi; S. haematobium and S. mansoni
are predominant causes of disease. An estimated 438.9 million
people were infected with hookworm in 2010, 819.0 million with
roundworms and 464.6 million with whipworm. STH altogether,
contributed to a total of 4.98 million years lived with disability
(YLDs) (Pullan, Smith, Jasrasaria & Brooker, 2014). Of these YLDs,
65% were attributable to hookworm, 22% to roundworm and the
remaining 13% to whipworm. In terms of geographical distribution,
around 67% of STH occurred in Asia contributing to 68% of the
YLDs (Pullan et al., 2014). Over 270 million preschool‐age children
and over 600 million school‐age children live in STH endemic areas
and an estimated 4 million pregnancies a year are complicated by
maternal hookworm infection alone (Bundy, Chan & Savioli, 1995;
WHO, 2005).
Anaemia is one of the most common side effects of infection with
STH or schistosomes, due to blood loss in the intestine or urinary
tract. Women in low‐ middle‐income countries (LMICs) are especially
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prone since they may be pregnant or lactating for as much as half of
their reproductive lives with over 50% of the pregnant women having
iron‐deficiency anaemia. Although iron‐deficiency anaemia is multi-
factorial, hookworm infection is an important contributor in endemic
areas, especially among women of reproductive age. An analysis on
anaemia epidemiology based on data from the Global Burden of
Diseases, Injuries and Risk Factors (GBD) 2010 study suggested that
hookworm and Schistosomiasis were among the top ten causes of
anaemia among females in 2010 (Kassebaum et al., 2014). It is the
leading cause of pathological blood loss in tropical and subtropical
regions (Pawlowski, Schad & Stott, 1991). Moreover there is a direct
association between the intensity of STH infection, blood loss and
consequent anaemia, especially for hookworms (Bundy et al., 1995;
Chan, Medley, Jamison & Bundy, 1994; Larocque, Casapia, Gotuzzo &
Gyorkos, 2005). The association between anaemia during pregnancy
and adverse pregnancy outcomes, including low birth weight (LBW),
preterm birth, perinatal mortality and infant survival has already
been documented (Rahman et al., 2016; Sifakis & Pharmakides,
2000). Furthermore, the chances of favourable pregnancy outcomes
are reduced by 30% to 45% in anaemic mothers, with their infants
having less than one half of normal iron reserves (Rahman et al.,
2016).
Mass deworming (treatment at a large scale irrespective of the
diseases status) along with the water, sanitation and hygiene (WASH)
interventions are generally accepted as effective measures to
prevent and treat STH and Schistosomiasis. However, findings from
existing studies are conflicting and the effectiveness of mass
deworming in improving various maternal and child health outcomes
is a current source of debate (Salam, Haider, Humayun & Bhutta,
2015; Turner et al., 2015). Critical appraisal of the existing studies
suggests that these studies fail to account for various factors that
could potentially modify the effectiveness of mass deworming
including nutritional status, type of infection, worm burden and
concomitant interventions (Barry, Simon, Mistry & Hotez, 2013;
Turner et al., 2015).
3.2 | The intervention
The World Health Organisation (WHO) recommends mass deworm-
ing (also called preventive chemotherapy, is the process of treating
large numbers of people in areas with a high prevalence of these
conditions) for STH and Schistosomiasis depending on prevalence of
worm infection. Preventive chemotherapy (deworming), using single‐
dose albendazole (400mg) or mebendazole (500mg), is recom-
mended as a public health intervention for pregnant women, after
the first trimester, living in areas where both:
(i) the baseline prevalence of hookworm and/or Trichur trichiura
infection is 20% or higher among pregnant women, and
(ii) anaemia is a severe public health problem, with a prevalence
of 40% or higher among pregnant women, in order to reduce
the worm burden of hookworm and T. trichiura infection
(WHO, 2017).
For Schistosomiasis, annual treatment with praziquantel in high
risk communities (>50% prevalence) and once every 2 years in
medium risk (>10% and <50% prevalence) is recommended and
women can be treated with praziquantel at any stage of pregnancy
and lactation (WHO, 2006). In addition to deworming; education on
health and hygiene and provision of adequate sanitation is also
recommended.
3.3 | How the intervention might work
STH and Schistosomiasis are a major public health concern since
these parasites feed on blood and affect the supply of nutrients
necessary for erythropoiesis; hence contributing to anaemia (Hotez &
Cerami, 1983; Torlesse & Hodges, 2000). Additionally, STH may also
lead to haemorrhage by releasing anticoagulant compounds, thereby
leading to iron‐deficiency anaemia. Infection during pregnancy leads
to an added demand for nutrients that are critical for foetal growth
and development (Abrams & Miller 2011; Blackwell, Snodgrass,
Madimenos & Sugiyama, 2010). Hookworms, in particular, along with
other STH and schistosomes have been associated with reductions in
haemoglobin and iron deficiency during pregnancy (Larocque et al.,
2005; Gyorkos, Gilbert, Larocque & Casapía, 2011; Muhangi et al.,
2007; Nurdia, Sumarni, Suyoko, Hakim & Winkvist, 2001; Ndyomu-
gyenyi, Kabatereine, Olsen & Magnussen, 2008b). Additionally, STH
and Schistosomiasis often occur with co‐infections in areas where
malnutrition is already prevalent (Martin, Blackwell, Gurven &
Kaplan, 2013).
Mass deworming is regarded as the most effective means of
controlling mortality and morbidity with STH and Schistosomiasis
(WHO, 2006, 2017). Preventive chemotherapy (either alone or in
combination) has been used as a public heath tool for preventing
morbidity due to infection usually with more than one helminth at a
time since many of the antihelminthic drugs are broad spectrum. In
1994, the WHO convened an informal consultation on hookworm
infection and anaemia in girls and women, which promoted the use of
antihelminthics in pregnancy after the first trimester in areas where
these infections are endemic and where anaemia is prevalent, but it
also recommended evaluation of the long‐term safety, particularly in
terms of birth outcomes (WHO, 1994). Women can be treated with
praziquantel for schistosomiasis at any stage of pregnancy and during
lactation. Deworming during pregnancy is often accompanied with
iron supplementation to reduce anaemia.
There are various factors that could potentially modify the
effectiveness of mass deworming including baseline nutritional status
(anaemia and body mass index [BMI]), type of STH infection,
treatment protocol, worm burden (particularly intensity of infection)
and concomitant interventions (such as iron supplementation and
other drugs such as praziquantel for Schistosomiasis). However,
given the limited number of studies assessing the impact of
deworming on maternal and newborn health outcomes (Salam
et al., 2015) and complex interactions between helminthic infections
and immune function, health and co‐infection risks (Blackwell, 2016),
it is difficult to ascertain how these factors interplay. Currently, it is
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difficult to establish whether mass deworming during pregnancy has
beneficial effects under certain conditions and limited effects under
others and there exists a possibility that it is only beneficial in women
with very high parasite burdens, dietary insufficiencies or both
(Blackwell, 2016). Moreover, all intestinal worms are not the same;
not all intestinal worms respond to the same deworming medication;
and not all infested individuals exhibit the disease. Reinfection
depends on the prevalence and intensity of infection as well as
environmental factors such as the WASH practices in the community.
Figure 1 highlights the logic model for this review.
3.4 | Why it is important to do the review
A Cochrane review on deworming in the second trimester of
pregnancy including four trials and 4,265 participants concluded
that there was insufficient evidence to recommend deworming in
pregnancy (Salam et al., 2015). There was no impact of single dose of
antihelminthics administered in the second trimester of pregnancy on
maternal anaemia, LBW, preterm birth and perinatal mortality. A
recent Campbell systematic review and network meta‐analysis based
on 47 randomised trials and over one million children, found little to
no overall effect on growth, attention and school attendance (Welch
et al., 2016). However, these reviews were conducted at the study
level, rather than using data for each individual participant, which
limits the power to detect effect modification by individual
participant characteristics that could potentially modify the effect
of deworming including baseline nutritional status, type of STH
infection, treatment protocol, worm burden and concomitant inter-
ventions (such as iron supplementation; Barry et al., 2013; Turner
et al., 2015).
IPD meta‐analysis refers to analysing data for each participant in
the existing studies (Tierney, Pignon et al., 2015; Tierney, Vale et al.,
2015). The term IPD refers to analysing data recorded for each
participant in contrast to the aggregate study data in meta‐analysis.
The advantage of an IPD analysis over aggregate meta‐analysis is
that it has the potential to improve the quality of both the data and
the analyses and consequently the reliability of the results (Tierney,
Vale et al., 2015). Furthermore, it also provides an opportunity to
re‐analyse the data for a range of other possibilities for example,
investigating if the treatment effects varies by participant character-
istics which is not possible with the aggregate data (Riley, Lambert &
Abo‐Zaid, 2010). An IPD approach will allow an evaluation of
variation in effect estimates by various individual, socio‐demographic
and environmental factors among pregnant women that could
potentially modify the effectiveness of mass deworming during
pregnancy.
Despite the availability of more recent global estimates on the
burden and interventions for STH and Schistosomiasis, additional
research is needed to understand the factors that explain the
variation in the effect estimates of recommended interventions to
prevent transmission. Existing studies fail to account for various
factors that could modify the effectiveness of mass deworming
including underlying host and environment factors. IPD meta‐analysis
would explore the question of whether mass deworming during
F IGURE 1 Logic model [Color figure can be viewed at wileyonlinelibrary.com]
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pregnancy is more effective for subgroups of women defined by
characteristics such as nutrition status and infection intensity. This
understanding could help develop targeted strategies to reach
pregnant women with deworming and guide policy regarding mass
deworming. A companion review using IPD and network meta‐
analysis to explore whether the effects of different types and
frequency of deworming drugs as well as their combination with food
or micronutrients vary with child‐level and study‐level characteristics
is also registerd with Campbell Collaboration (Welch et al.).
4 | Objectives
The objective of the review is to use IPD meta‐analysis to explore
whether the effect of mass deworming among pregnant women on
maternal and birth outcomes vary with individual characteristics
(nutritional status, anaemia), intensity of infection (as assessed by egg
count), infection status (including species of worm), socioeconomic
status, sanitation environment and other co‐interventions.
5 | METHODOLOGY
The protocol was registered with the Campbell Collaboration (Salam
et al.) and reported according to the preferred reporting items for
systematic reviews and meta‐analyses for protocols (PRISMA‐P)
(Moher et al., 2015). Results of the review are reported using the
Preferred Reporting items for Systematic Reviews and Meta‐
analyses of individual patient data (PRISMA‐IPD) Statement (Stewart
et al., 2015).
5.1 | Criteria for including and excluding studies
We included studies that met the following eligibility criteria
5.1.1 | Types of study designs
We included individually randomised controlled trials (RCT); cluster
RCTs and quasi randomised studies (studies where non‐random
assignment is determined by factors that are out of the control of the
investigator) as these were the most appropriate design for the IPD
meta‐analysis. No language or date restrictions were applied.
5.1.2 | Types of participants
Participants were pregnant women receiving preventive or ther-
apeutic deworming drugs for STH and schistosomiasis.
5.1.3 | Types of interventions
We included mass deworming using any drug or a combination of
drugs (including levamisole, mebendazole, albendazole, praziquantel
and pyrantel) for STH and schistosomiasis with or without
co‐interventions compared to placebo or control (no mass deworm-
ing). Co‐interventions could be food provision, micronutrient
supplementation, iron and/or folic acid supplementation, hygiene
interventions or education. We included studies where the co‐
interventions were similar in the intervention and control groups to
assess the impact of mass deworming.
5.1.4 | Types of outcome measures
Following primary and secondary outcomes were reported; however
we did not use the list of outcomes as a criteria for inclusion of
studies in the review:
Primary outcomes:
• Maternal anaemia at term (haemoglobin less than 11 g/dl)
• Maternal infection intensity (as reported by the study authors)
Secondary outcomes:
• Maternal haemoglobin at term
• Maternal ferritin
• Maternal anthropometric measures (height and weight)
• Maternal body mass index (BMI)
• Birth weight
• LBW (less than 2500 g)
• Preterm birth (birth before 37 weeks of gestation)
• Perinatal mortality (includes foetal death after 28 weeks of
gestation and infant death that occurs at less than seven days
of life)
• Stillbirth
• Congenital abnormalities
• Infant mortality
5.1.5 | Duration of follow‐up
We did not restrict inclusion based on the duration of follow‐up.
5.1.6 | Types of settings
The settings included any area where STH or schistosomes are
endemic. These could include studies conducted in either community
settings or facility settings including hospitals, antenatal clinics,
primary healthcare centres etc.
5.2 | Search strategy
We conducted the search in the following databases till 21 March
2018: MEDLINE, CINAHL, LILACS, EMBASE, the Cochrane Library,
Internet Documents in Economics Access Service (IDEAS), Google
Scholar, Web of Sciences, Social Services Abstracts, WHO Global
Health Library, Global Health CABI and CAB Abstracts. We also
searched grey literature in OpenGrey and websites of relevant
organisations such as the World Bank, World Food Program and
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International Food Policy Research Institute. We also contacted
authors of studies and members of our advisory board for any
unpublished studies or grey literature reporting eligible studies. We
checked reference lists of relevant studies and reviews. We also
searched for trials registered with ClinicalTrials.gov and the WHO
International Clinical Trials Registry Platform (http://www.who.int/
trialsearch/).
Titles and abstracts were screened in duplicate by two reviewers.
We pilot‐tested the screening criteria at both title and abstract
screening stage and full text stage. We used the PRISMA flow
diagram to report eligibility of studies. We retrieved full text of all
studies which pass this first level screening. The full text review were
also done in duplicate by two reviewers, and agreement was reached
by consensus. Disagreements were resolved by consultation with a
third reviewer. No language or date limits were applied. The search
strategy is attached as Appendix 1.
5.3 | Description of methods used in primary
research
RCTs of mass deworming include two‐arm trials as well as factorial
trials, with women allocated either individually or by cluster‐
randomisation.
5.4 | Details of study coding categories
We extracted the study characteristics including details of the
populations, setting, socio‐demographic characteristics, interven-
tions, comparators, outcomes and study design in duplicate. The
characteristics extracted from the included studies are specified in
Appendix 2.
5.5 | Quality assessment and grading
Risk of bias was assessed at the study as well as the outcome level.
At the study level, two independent reviewers performed quality
appraisal for each study using the Cochrane risk of bias tool which
assessed selection bias, performance bias, detection bias, attrition
bias and reporting bias (Higgins, Altman & Sterne, 2011).
Disagreements were resolved by discussion or consultation with
a third reviewer. At the outcome level, we summarised the quality
of evidence according to the outcomes as per the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) criteria (Walker et al., 2010). A grade of 'high',
'moderate', ‘low’ and ‘very low’ was used for grading the overall
evidence indicating the strength of an effect on specific health
outcome based on methodological flaws within the component
studies, consistency of results across different studies, generali-
sability of research results to the wider patient base and how
effective the treatments have shown to be (Balshem et al., 2011).
The two reviewers discussed ratings and reached consensus.
Disagreements were resolved by consulting a third reviewer. We
developed a summary of findings table to show the effects for the
primary outcomes of maternal anaemia and infection intensity; as
well as the secondary outcomes of preterm birth, LBW and
perinatal mortality since these outcomes assess long‐term effects,
particularly in terms of birth outcomes.
5.6 | Statistical procedures and conventions
Trialists of the included trials provided IPD by electronic transfer
where possible or other means as needed. The individual trial data
were recoded as required and checked with respect to range, internal
consistency, missing values, outliers, errors and consistency with
published reports. Trial details such as randomisation methods and
intervention details were cross‐checked against published reports,
trial protocols and data collection sheets. Inconsistencies or missing
data were discussed with the individual trialists and attempts were
made to resolve any problems by consensus. We did not exclude any
study based on the way the outcomes were reported.
Data were prepared into a flat spread‐sheet with the same
fields for every study. We considered the missing values for each
variable as missing at random (MAR). For this IPD, we restricted
our analysis to conventional complete case analyses, that is,
removing subjects with a missing value from the analyses, since
the missing data were considered to be non‐trivial. For future
updates, we plan to use multiple imputation to impute the missing
values for covariates at baseline (individual participant level
variables) and outcome variables (primary and secondary out-
comes). Imputation was planned to be done using Proc MI in SAS/
STAT (SAS Institute Inc., Cary, NC). We plan to assess the
robustness of the results by running a separate model excluding
imputed data (i.e., complete case analysis). We plan to include
studies with missing data on more than 50% of outcome or
covariate data in the complete case analysis only for future
updates.
Descriptive characteristics of each study were presented, with
details on the participant characteristics, environment, worm species,
prevalence, intensity of infection, geographic location, interventions,
comparator, outcomes and risk of bias assessment. We accounted for
clusters (such as villages, schools or households) as nested within
each study. Following data items were collected:
Individual level:
• Infection intensity with Ascaris, Trichuris, hookworm and schisto-
somes (across four levels of none, light, moderate and heavy, using
the WHO cutoffs for each helminth, available at: http://apps.who.
int/iris/bitstream/10665/44671/1/9789241548267_eng.pdf)
• Anaemia status (using WHO cutoffs by age and altitude of non‐
anaemic, mild, moderate and severe, http://www.who.int/vmnis/
indicators/haemoglobin.pdf)
• Undernutrition (BMI < 18.5 kg/m2)
• Socioeconomic status (as defined by trial authors): We assessed
whether the measurement of socioeconomic status can be
compared across study settings and time.
• Deworming drug used.
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Environmental level:
• WASH practices (as defined by trial authors)
• Population level infection intensity (using WHO cut‐offs for each
worm‐type, as above)
We calculated the standardised difference between the published
data and the IPD received from authors for baseline characteristics
and baseline outcome assessment. For endline (outcome measures),
we replicated the effect measures reported in study publications and
calculated the standardised difference between the IPD received and
the study report (Austin, 2009).
The comparison of interest for the pairwise analysis included (but
not restricted to) any deworming drug versus no deworming. We
used a two‐step process to meta‐analysis. We conducted pairwise
analyses for the comparison of interest by entering all IPD data into a
multilevel model, with each study as one cluster. We expected
considerable heterogeneity between studies for each outcome;
therefore, we used a random effects model. Where IPD was not
available for all trials, we used a two‐part model with one part based
on IPD data and the second part based on aggregate data from
studies which did not provide IPD (Fisher, Copas, Tierney & Parmar,
2011; Riley & Steyerberg, 2010; Riley et al., 2008). We planned to
conduct pair‐wise comaprisons for one deworming drug versus other
deworming drug or a combination of deworming drugs, however we
could not perform such analysis due to limited data.
We accounted for clustering as above by nesting clusters within
studies. We decided on a set of pre‐defined covariates with advice
from our advisory board and co‐authors. We accounted for the pre‐
defined covariates of infection intensity, baseline anaemia, baseline
nutritional status, socioeconomic status and maternal education in
the model. We did not plan to conduct network meta‐analysis based
on our previous experience with limited number of studies in the
domain (Salam et al., 2015).
5.7 | Measures of treatment effects
We separately analysed the dichotomous and continuous outcomes.
For dichotomous outcomes, we presented the results as summary
risk ratios (RRs) with 95% confidence intervals (CI). We presented
continuous outcome data as either a mean difference (MD), if
outcomes have been measured on the same scale, or a standardised
mean difference (SMD), if outcomes have been measured on different
scales, with 95% CI. For each outcome, we reported the results for
the evidence from study results pooled at the aggregate level
(adjusted for covariates) and the evidence pooled using IPD (adjusted
for covariates).
5.8 | Assessment of clinical and methodological
heterogeneity within treatment comparisons
Heterogeneity across trials in terms of subject characteristics,
trial methodologies and treatment protocols was assessed using visual
plots, tables and homogeneity statistics. We assessed heterogeneity
using visual inspection of forest plots for pairwise analyses as well as
statistical tests of heterogeneity (I2). In addition to I2, we also assessed
between‐study variance (variation across study findings beyond
random sampling error) by the variance of the distribution of the
true study effects, commonly denoted as τ2.
5.9 | Publication bias
We planned to generate a funnel plot for comparisons and
outcomes with >10 studies. We planned to use Egger’s test for
asymmetry and visual inspection to assess the presence of
publication bias and/or selective reporting. However, none of the
comparisons or outcomes included >10 studies and hence we
could not assess for publication bias.
5.10 | Subgroup analyses
Where sufficient data were available, sub‐group analyses was planned
to be conducted to assess effects across both individual‐level as well
as environment‐level characteristics. We compared the results of
models with subgroup analyses by assessing the size of quantitative
or qualitative differences in effects, the statistical significance of tests
for interactions, assessing between‐study variance and assessing the
goodness of fit of the models using the likelihood ratio. Before
conducting subgroup analyses, we assessed the distribution of each
variable. If there were insufficient participants in some categories, the
levels were combined. The following individual and environment level
effect modifiers were planned to be assessed (data permitting):
Individual Level:
• Infection intensity with Ascaris, Trichuris, hookworm and schisto-
somes (across four levels of none, light, moderate and heavy, using
the WHO cutoffs for each helminth, available at: http://apps.who.
int/iris/bitstream/10665/44671/1/9789241548267_eng.pdf)
• Anaemia status (using WHO cutoffs by age and altitude of non‐
anaemic, mild, moderate and severe, http://www.who.int/vmnis/
indicators/haemoglobin.pdf)
• Undernutrition (BMI < 18.5 kg/m2)
• Socioeconomic status (as defined by trial authors): We assessed
whether the measurement of socioeconomic status can be
compared across study settings and time.
Environmental Level:
• WASH practices (as defined by trial authors)
• Population level infection intensity (using WHO cut‐offs for each
worm‐type, as above)
5.11 | Sensitivity analyses
Where sufficient data were available, we planed to conduct
sensitivity analyses to assess robustness of results when restricted
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to studies at low risk of bias for sequence generation, allocation
concealment and blinding of participants. We planned to assess
whether results were robust to excluding imputed data (i.e., complete
case analysis).
5.12 | Data management
Data were transferred to SAS as a common platform for all studies,
using a common data dictionary. We checked IPD data for
consistency immediately upon receiving datasets for outlier indivi-
duals (e.g. with duplicate participant IDs, unrealistic date ranges). We
compared the IPD from authors with the aggregate data reported in
the articles. Any missing or unusual data were flagged for discussion
with the trial author or statistician. We asked for clarification from
the authors to establish reasons for the errors, and correct them if
possible. Any requests for authors were discussed when the data
were provided, such as clarification of trial risk of bias, conduct or
eligibility criteria. We also ran the same statistical analysis as the
authors to check for consistency with the published paper (Stewart
et al., 2015). We requested statements of ethics approval from each
study and we did not include data from studies that did not receive
ethics approval. We requested that all data be transferred without
any identifiers.
5.13 | Treatment of qualitative research
We did not plan to include qualitative research.
6 | RESULTS
The results of this review are reported according to the PRISMA‐IPD
reporting guidelines (checklists in Additionals Table 1).
6.1 | Search results
We searched all databases up to March, 2018. Figure 2 provides a
search flow diagram. We identified a total of 23406 record through
the search strategy provided in Appendix 1. A total of 31 papers
(Atukorala, de Silva, Dechering, Dassenaeike & Perera, 1994; Villar
et al., 1998; Abel, Rajaratnam, Kalaimani & Kirubakaran, 2000; Ács,
Banhidy, Puho & Czeizel, 2005; Adam, Elwasila & Homeida, 2005;
Christian, Khatry & West, 2004; De Silva, Sirisena, Gunasekera,
Ismail & de Silva, 1999; Deepti & Nandini, 2015; Elliott, Mpairwe
et al., 2005; Elliott, Namujju et al., 2005; Elliott et al., 2007; Gyorkos,
Larocque, Casapia & Gotuzzo, 2006; Gyorkos, Gilbert et al., 2011;
Larocque et al., 2006; Liabsuetrakul et al., 2009; Tehalia, 2011;
Mpairwe et al., 2011; Millard et al., 2014; Nampijja et al., 2012;
Ndibazza et al., 2010; Ndibazza et al., 2012; Ndyomugyenyi,
Kabatereine, Olsen & Magnussen, 2008a; Olveda et al., 2016;
Torlesse & Hodges, 2000; Torlesse & Hodges, 2001; Tweyongyere
et al., 2008; Tweyongyere et al., 2009; Tweyongyere et al., 2011;
Tweyongyere et al., 2013; Urassa, Nystrom & Carlsted, 2011; Webb,
Mawa et al., 2011; Webb, Kyosiimire‐Lugemwa et al., 2012) based on
16 studies assessed mass deworming during pregnancy and were
deemed eligible for the review. These 16 studies were assessed for
TABLE 1 Eligibility for IPD
Study ID Study Design Eligible for IPD Reason for Exclusion
Elliott 2005 (Ndibazza et al., 2010) Randomised Controlled Trial Yes
Larocque 2006 (Larocque et al., 2006) Randomised Controlled Trial Yes
Ndyomugyenyi 2008 (Ndyomugyenyi
et al., 2008a)
Randomised Controlled Trial Yes
Torlesse 2001 (Torlesse & Hodges, 2001) Randomised Controlled Trial Yes
Urassa 2011 (Urass et al., 2011) Randomised Controlled Trial Yes
Deepti 2015 (Deepti & Nandini, 2015) Randomised Controlled Trial Yes
Tehalia 2011 (Tehalia, 2011) Randomised Controlled Trial Only abstract available with insufficient information
and the authors could not be contacted
Villar 1998 (Villar et al., 1998) Randomised Controlled Trial Only abstract available with insufficient information
and the authors could not be contacted
Olveda 2016 (Olvedaet al., 2016) Randomised Controlled Trial Yes
Atukorala 1994 (Atukorala et al., 1994) Before‐after study Study design not appropriate
Abel 2000 (Abel et al., 2000) Before‐after study Study design not appropriate
Christian 2004 (Christian et al., 2004) Prospective Cohort Study design not appropriate
de Silva 1999 (De Silva et al., 1999) Cross‐sectional survey Study design not appropriate
ACS 2005 (Ács et al., 2005) Case‐control study Study design not appropriate
Adam 2005 (Adam et al., 2005) Prospective cohort Study design not appropriate
Liabsuetrakul 2009 (Liabsuetrakul et al.,
2009)
Prospective cohort Study design not appropriate
Abbreviation: IPD, individual participant data.
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IPD eligibility and seven studies with 8,515 participants were
identified to be eligible for IPD. Major reasons for exclusion from
IPD inlcuded:
(i) study design not being appropriate and;
(ii) only abstracts were available with insufficient information and
the trialists could not be contacted.
Out of the seven studies found eligible for IPD, three trials were
subsequently included in the IPD since the authors of these three
trials provided data for IPD (Elliott, Mpairwe et al., 2005;
Olvedaet al., 2016; Urass et al., 2011). Table 1 details the study
eligibility for IPD.
6.2 | Characteristics of studies
A total of seven studies including 8,515 pregnant women were
eligible for IPD. All of these studies were RCTs. Studies were
conducted in India, Philippines, Peru, Sierra Leone, Tanzania and
Uganda between 2001 and 2016. The deworming drugs provided in
these studies included albendazole, mebendazole, praziquantel,
ivermectin or a combination of these. Majority of the studies
provided mass deworming for STH only; while one study (Olveda
et al., 2016) provided deworming for schistosomiasis alone; and one
study (Elliott, Mpairwe et al., 2005) targeted both STH and
schistosomiasis. The sample size ranged from 184 pregnant women
to 3,080 pregnant women. The most common co‐intervention was
iron/folic acid supplementation while other interventions included
food supplementation, anti‐malarial drug administration and educa-
tion. Maternal and birth outcomes were assessed in the third
trimester and at the time of delivery in all the included studies. Table
2 describes the characteristics of studies eligible for IPD. Out of the
seven studies, three trials were subsequently included in the IPD
(Elliott, Mpairwe et al., 2005; Olveda et al., 2016; Urass et al., 2011)
and further descritipion is provided in the following sections.
7 | QUALITY OF STUDIES
The quality of the studies was assessed using the Cochrane risk of
bias assessment criteria. Overall, the included studies were judged to
be of fairly good quality. For random sequence generation, five
studies were judged to be at low risk of bias while two studies
(Ndyomugyenyi et al., 2008a; Urass et al., 2011) were rated as
unclear since the method of sequence generation was not specified.
Allocation concealment was judged to be adequately done in three
studies (Larocque et al., 2005; Deepti & Nandini, 2015; Elliott,
Mpairwe et al., 2005); three studies did not clearly specify the
concealment of allocation and were judged to be at unclear risk
(Torlesse & Hodges, 2000; Ndyomugyenyi et al., 2008a; Urass et al.,
2011) while one study did not adequately conceal the allocation and
was rated as high risk for allocation concealment (Olveda et al.,
2016). All the included studies either adequately blinded the
participants, personnels and outcome assessors or we felt that lack
of blinding would be unlikely to affect the results and hence all the
studies were rated to be a low risk for blinding. Four studies were
rated at low risk of attrition bias while two studies were rated to be
at high risk of attrition bias (Torlesse & Hodges, 2000; Urass et al.,
2011). All the studies were judged to be at low risk of bias for
selective reporting since the outcomes specified in the study protocol
or methodology section of the study were reprotred in the outcome
section. We judged one study as unclear risk of bias for ‘other bias’
since in the (Elliott, Mpairwe et al., 2005) study, enrolment was
stopped after 104 women due to new guidelines by the WHO which
recommended inclusion of treatment of women with schistosomiasis.
Figure 3a depicts the risk of bias for the studies included in the
F IGURE 2 Search flow diagram
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review while Figure 3b depicts the risk of bias for the studies
subsequently included in the IPD.
8 | CONTACTING AUTHORS AND YIELD
OF THE STUDIES
Trial authors were contacted for all seven trials deemed eligible
for the IPD. Out of the seven trials, we received data from three
trials (Elliott, Mpairwe et al., 2005; Olveda et al., 2016; Urass et al.,
2011); data from two trails were lost (Deepti & Nandini, 2015;
Torlesse & Hodges, 2000; trialists were not able to retrieve the
data); one trialist refused to share the data (Larocque et al., 2006)
while one could not be contacted due to severe health conditions
(Ndyomugyenyi et al., 2008a). In terms of the number of
participants; out of 8,515 potential IPD participants; data were
captured for 5,957 participants. Figure 4 depicts the number of
studies and participants eligibility for IPD.
F IGURE 3 (a) Risk of bias for the included trials. (b) Risk of bias for the trials included in IPD. IPD, individual participant data [Color figure
can be viewed at wileyonlinelibrary.com]
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9 | DATA AND ANALYSIS
9.1 | Data preparation: missingness analysis
Tables 3 and 4 provides an overview of the missing values for the
baseline and endline variables in the data sets from each of the trial.
9.2 | Data replications
Replication of the published study results was conducted for all three
studies. The standardised differences between the published and
replication results were all below 0.10 for all outcome measures and
covariates. There were instances where the standardised difference
could not be calculated because the published results did not report
the outcome measure in question. Table 5 reports the standardised
differences between the published and reproduced results for
outcome measures.
10 | IPD FEASIBILITY AND CHANGES
TO THE ANALYSIS MODEL
Based on the availability of data, we could only analyse one
comparison of interest (mass deworming with any drug versus no
mass deworming). The planned analysis and final model was also
modified accordingly. Table 6 provides a comparison of the original
analysis plan and the actual analysis model.
11 | MAIN EFFECTS
This section provides the overall results for mass deworming compared
to no mass deworming on the following outcomes: maternal anaemia;
maternal infection intensity (T.Trichiura and hookworm); LBW and
preterm birth. All of the seven trials deemed eligible for the IPD
contributed data towards the aggregate estimate while data from three
trials (Elliott, Mpairwe et al., 2005; Olveda et al., 2016; Urass et al., 2011)
contributed to the IPD estimate. We report results for the evidence from
study results pooled at the aggregate level (adjusted for covariates) and
the evidence pooled using IPD (adjusted for covariates). However we
advise caution in interpreting these findings due to small sample sizes.
Following this section, we describe effect modifier analyses for
each planned effect modifier for each outcome of interest.
11.1 | Maternal anaemia
The effect estimates from aggregate evidence were of similar size and
direction as the IPD effect estimates. Three trials reported data on
maternal anaemia. Mass deworming led to a 23% reduction in maternal
anaemia (RR: 0.77, 95% CI: 0.73–0.81; three trials; 5,216 participants;
moderate quality evidence). Table 7 reports the aggregate and IPD
adjusted estimates.
11.2 | T.Trichiura intensity
Two trials reported T.Trichiura intensity showing no evidence of impact
of mass deworming on any infection (RR: 0.69, 95% CI: 0.42–1.13; two
trials; 2,867 participants; moderate quality evidence). We attempted to
categorise the participants according to the intensity of infection (none,
light, moderate and heavy); however there were too few participants in
each category to draw meaningful conclusions. The effect estimates
from aggregate evidence were of similar size and direction as the IPD
effect estimates. Table 8 reports the aggregate and IPD adjusted
estimates for maternal T.Trichiura intensity.
No. of studies: 
[VALUE]
2
1 1
Received Lost Refused No response
Total number of Studies (N=7)
No. of 
parcipants: 
[VALUE]
684 1042 832
Received Lost Refused No response
Total number of Parcipants (N=8515)
F IGURE 4 Number of eligible studies
and participants for IPD. IPD, individual
participant data [Color figure can be
viewed at wileyonlinelibrary.com]
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11.3 | Hookworm intensity
Two trials reported hookworm intensity. Overall there was no
evidence of impact of mass deworming on any hookworm infection
(RR: 0.52, 95% CI: 0.18, 1.47; two trials; 2,867 participants; moderate
quality evidence). We attempted to categorise the participants
according to the intensity of infection (none, light, moderate and
heavy); however there were too few participants in each category to
draw meaningful conclusions. The effect estimates from aggregate
evidence were of similar size and direction as the IPD effect
estimates. Table 9 reports the aggregate and IPD adjusted estimates
for maternal hookworm intensity.
11.4 | Low birth weight
Two trials reported LBW suggesting no evidence of an impact of
mass deworming on LBW (RR: 0.89, 95% CI: 0.67–1.18; two trials;
2,267 participants; moderate quality evidence). The effect estimates
from aggregate evidence were of similar size and direction as the IPD
effect estimates. Table 10 reports the aggregate and IPD adjusted
estimates for LBW.
11.5 | Preterm birth
Two trials reported preterm birth suggesting no evidence of an
overall impact (RR: 0.69, 95% CI: 0.47–1.03; two trials; 2,707
participants; moderate quality evidence). The effect estimates from
aggregate evidence were of similar size and direction as the IPD
effect estimates. Table 11 reports the aggregate and IPD adjusted
estimates for preterm birth.
12 | EFFECT MODIFIER ANALYSES
Based on the availability of the data, we could only assess for
effect modification by baseline Trichiura infection, maternal
anaemia at baseline and maternal BMI at baseline. The overall
model suggested a marginally significant impact of deworming on
maternal anaemia (RR: 0.77, 95% CI: 0.73–0.81) with no evidence
of impact on Trichiura infection, hookworm infection, LBW and
preterm birth. The test for interaction was not statistically
significant across the levels of Trichiura infection at baseline,
maternal anaemia at baseline or maternal BMI at baseline for any
of the outcomes. There was no evidence of effect modification by
baseline Trichiura infection, maternal anaemia at baseline and
maternal BMI at baseline. Table 12 depicts the estimates for full
model and effect modification.
These findings are summarised in the summary of findings table
(Table 13). All the outcomes were rated to be of moderate quality
evidence. The evidence was downgraded by one level due to the
study limitations since estimates are based on a sleceted sample
received to conduct IPD.T
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13 | DISCUSSION
13.1 | Summary of main results
This IPD meta‐analysis is based on the data from three trials with
5,957 participants. The effect estimates from aggregate evidence
were of similar size and direction as the IPD effect estimates.
Findings from this IPD suggest reduction in anaemia among pregnant
women with mass deworming. There was no evidence of effect on
any of the other outcomes including Trichiura infection, hookworm
infection or any of the pregnancy outcomes including LBW and
preterm birth. Findings of no impact of mass deworming on infection
intensity could be attributable to the fact that majority of the study
population in the included studies were either not infected or lightly
infected which could have diluted the impact. Based on the
availability of the data, we could only assess for effect modification
by baseline Trichiura infection, maternal anaemia at baseline and
maternal BMI at baseline. There was no evidence of effect
modification by Trichiura intensity at baseline, maternal anaemia at
baseline and maternal BMI at baseline; however we advise caution in
interpreting these findings due to limited number of participants
included in the analysis.
13.2 | Overall completeness and applicability
of evidence
Findings from this IPD analysis is based on 70% of the existing data
deemed eligible for IPD (5957 participiants of 8515 participants).
The studies included in this review were conducted among pregnant
TABLE 3 Missing values for baseline variables
Studies
Baseline variables
Elliott, 2005 Olveda, 2016 Urassa, 2011 Total
N = 5,943(n = 2,505) (n = 362) (n = 3,076)
Education 0.15% (4) 0.55% (2) NA 0.1% (6)
Parity NA 0% 0% 0%
Gravidity 0% NA 0% 0%
Weight 0.15% (5) 0% NA 0.08% (5)
Height 1.12% (28) 0% NA 0.5% (28)
Anaemia 0.5% (12) 0% 0% 0.2% (12)
S.Japonicum intensity NA 0% NA 0%
S.Mansoni intensity 0% NA NA 0%
A.Lumbricoides intensity NA 39% (141) NA 2.4% (141)
T.Trichiura intensity 0% 19% (69) NA 1.15% (69)
Hookworm intensity 0% 64% (231) NA 3.88% (231)
Ascaris intensity 0% NA NA 0%
Socioeconomic status 7.3% (183) 0% NA 3.08% (183)
TABLE 4 Missing values for endline variables
Studies
Endline variables
Elliott, 2005 Olveda, 2016 Urassa, 2011 Total
N = 5,943(n = 2,505) (n = 362) (n = 3,076)
Weight NA 0.82% (3) NA 0.05% (3)
Anaemia 13.53% (339) 0.82% (3) 12.51% (385) 12.23% (727)
S.Japonicum intensity NA 63.5% (230) NA 3.87% (230)
S.Mansoni intensity 18% (451) NA NA 18% (451)
A.Lumbricoides intensity NA 0% NA 0%
T.Trichiura intensity 18% (451) 26% (94) NA 9.17% (545)
Hookworm intensity 18% (451) 0% NA 18% (451)
Ascaris intensity 18% (451) 0% NA 18% (451)
Birth weight 23.91% (599) 0.27% (1) NA 10.1% (600)
LBW 23.91% (599) 0.27% (1) NA 10.1% (600)
Preterm birth 6.38% (160) 0% NA 2.7% (160)
16 of 27 | SALAM ET AL.
women in LMIC settings. One of the three trials included in the IPD
analysis provided daily iron folate supplements (36 mg iron; 5 mg
folate) along with the deworming drugs.
We conducted an extensive search of electronic databases, with
advice from the Campbell Collaboration International Development
Group information scientist. We screened 23406 articles and
updated this search to March 2018. We report the systematic
review according to the reporting guidelines for IPD meta‐analysis
(PRISMA‐IPD). We published and followed an a priori protocol (Salam
et al). Our systematic review and IPD analysis was approved by the
Research Ethics Boards at SickKids. We developed a data sharing
TABLE 5 Standardised differences between published and repro-
duced results for outcome measures by eligible studies
Studies
Variables Elliott, 2005 Olveda, 2016 Urassa, 2011
Maternal weight NA 0.00 NA
Maternal anaemia 0.02 NA 0.00
Maternal haemoglobin 0.04 0.005 NA
S. Japonicum intensity NA NA NA
S. Mansoni intensity 0.00 NA NA
Ascaris intensity 0.00 NA NA
Trichuris intensity 0.04 NA NA
Hookworm intensity 0.00 NA NA
Birth weight 0.007 0.003 NA
LBW 0.05 0.05 NA
SGA NA 0.00 NA
Preterm birth NA NA NA
Perinatal mortality 0.00 NA NA
Congenital anomaly 0.01 NA NA
Infant survival NA NA NA
TABLE 6 Comparison of the original analysis plan and actual model employed
Planned analysis Actual analysis
Outcomes Maternal anaemia at term Maternal anaemia at term (Hb < 109 g/l)
Maternal infection intensity Trichiura intensity (none vs. any (light/moderate/heavy) intensity)
Maternal haemoglobin at term Hookworm intensity (none vs. any (light/moderate/heavy) intensity)
Maternal ferritin
Maternal anthropometric measures LBW (<2500 g)
Preterm birth (<37 weeks of gestation)
Maternal BMI
Birth weight
Low birth weight
Preterm birth
Perinatal mortality
Stillbirth
Congenital abnormalities
Infant Mortality
Covariates Schistosoma intensity Hookworm intensity (none vs. any (light/moderate/heavy) intensity)
Ascaris intensity Trichiura intensity (none vs. any (light/moderate/heavy) intensity)
Hookworm intensity Haemoglobin (Hb < 109 g/l)
Trichuria intensity
Haemoglobin
BMI
Socio‐economic status
Deworming drug
WASH practices
Population level worm intensities
Effect Modifiers BMI (<18.5 kg/m2, 18.5 to 25 kg/m2) BMI (<18.5 kg/m2, 18.5 to 25 kg/m2)
Anaemia status (none, mild, moderate, severe) Aanemia (Hb<109 g/l)
Schistosoma intensity (light, moderate, heavy) Trichiura intensity (none vs. any (light/moderate/heavy) intensity)
Ascaris intensity (light, moderate, heavy)
Hookworm intensity (light, moderate, heavy)
Trichuria intensity (light, moderate, heavy)
Any STH or Schistosoma infection (light, moderate, heavy)
Concomitant interventions
TABLE 7 Imapct of mass deworming on maternal anaemia
Analysis Effect estimates (RR and 95% CI)
Aggregate adjusted 0.94 (0.89–0.99)
IPD adjusted 0.77 (0.73‐0.81)
TABLE 8 Mass deworming on T.Trichiura intensity (any infection)
Analysis Effect estimates (RR and 95% CI)
Aggregate adjusted 1.06 (0.87, 1.30)
IPD adjusted 0.69 (0.42–1.13)
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agreement that was signed by all studies that contributed data. Study
authors were invited to join the Investigator’s Collaborative,
participate in meetings and contribute to the final report. Our
process and conduct of the IPD was driven by consultation with our
expert Advisory board which included statistical, parasitology and
nutrition expertise.
13.3 | Quality of the evidence
The trials included in the IPD were judged to be of fairly good quality.
All of the included studies were judged to be at low risk of bias for
blinding of participants, personnel and outcome assessor; and
selective reportong. One of the included studies was judged to be
at high risk of bias for allocation concealment while two studies were
at high risk for attrition bias. The overall outcome quality was judged
to ‘moderate’ based on the GRADE criteria. The outcome quality was
downgraded due to study limitations since the estimates are based
on selected sample eligible for IPD.
13.4 | Limitations and potential biases in the
review process
Despite of receiving majority of the existing data (70%) to conduct IPD,
there were a few limitations. One limitation of this review is that we did
not receive data from all eligible studies. Another limitation is that we
were unable to assess effect modification by pre‐idnetified effect
modifiers. The trials did not capture many of the variables of interest
that restricted our analysis. Very few trials reported outcomes
according to the baseline level of infection intensities and hence those
conclusions could not be drawn. In terms of the infection intensities, the
population studied were either not infected or lightly infected and
hence it was difficult to categorise the sample according to the intensity
of infection and have meaningful estimates. Trials did not report
baseline data on the individual and environmental level effect modifiers
and hence it was difficult to assess the effect modification. Variables like
socio‐economic status were least studied and where reported, had
different definitions and hence could not be accounted for. None of the
included studies assessed any co‐interventions including WASH
practices and hence the impact of co‐interventions could not be
assessed. We could not assess for publication bias given the small
number of included studies; however, considering the small universe of
studies in the domain, the issues related to publication and small study
sizes cannot be ignored.
13.5 | Agreements and disagreements with other
studies or reviews
The most recent Cochrane meta‐analysis (Salam et al., 2015) on
deworming for STH during pregnancy concluded that there was
insufﬁcient evidence to recommend deworming for STH. This
review also highlighted the need for future well‐designed, large
scale RCTs to establish the beneﬁt. These findings were based on
four trials including 4265 participants. This review has some
differences compared to our review. The inclusion criteria for this
TABLE 9 Mass deworming on hookworm intensity (any infection)
Analysis Effect estimates (RR and 95% CI)
Aggregate adjusted 0.39 (0.04, 3.93)
IPD adjusted 0.52 (0.18‐1.47)
TABLE 10 Mass deworming on LBW
Analysis Effect estimates (RR and 95% CI)
Aggregate adjusted 1.04 (0.79, 1.38)
IPD adjusted 0.89 (0.67, 1.18)
TABLE 11 Mass deworming on preterm birth
Analysis Effect estimates (RR and 95% CI)
Aggregate adjusted 0.84 (0.51, 1.39)
IPD adjusted 0.69 (0.47, 1.03)
TABLE 12 Potential effect modification of mass deworming during pregnancy by baseline infection intensity, anaemia status and BMI
Categories Outcomes (RR with 95% CI)
Maternal anaemia Trichiura infection Hookworm infection LBW Preterm birth
Mass deworming
(overall)
0.77 (0.73–0.81) 0.69 (0.42, 1.13) 0.52 (0.18, 1.47) 0.89 (0.67–1.18) 0.69 (0.47–1.03)
Trichiura Intensity
at baseline
Not infected 0.93 (0.80–1.09) – – 0.67 (0.43–1.04) 0.82 (0.50–1.36)
Infected 0.81 (0.65‐1.02) – – 1.12 (0.68–1.86) 1.32 (0.68–2.55)
Maternal Anaemia
at baseline
Normal – 0.65 (0.53–0.81) 0.51(0.42–0.62) 0.80 (0.56–1.13) 0.57 (0.36–0.92)
Anaemia
(Hb < 11 g/dl)
– 0.60 (0.46‐0.78) 0.56 (0.45–0.70) 1.01 (0.68–1.49) 0.71 (0.41–1.22)
Maternal BMI
at baseline
Normal 0.88 (0.77–1.01) 0.61 (0.51–0.73) 0.49 (0.42–0.57) 0.86 (0.65–1.15) 0.72 (0.48–1.09)
Low ( < 18.5 kg/m2) 1.10 (0.74–1.63) 1.53 (1.01–2.32) 0.36 (0.17–0.78) 1.11 (0.47–2.64) 0.82 (0.20–3.34)
Note: Bold font indicates statitiscally significant estimates.
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Cochrane review was limited to deworming for STH alone while
our IPD meta‐analysis also included trials with deworming for
schistosomiasis. The Cochrane review reported no impact of mass
deworming for STH on maternal anaemia while findings from our
review suggests reduction in maternal anaemia associated with
mass deworming,
13.6 | Implications for policy
This systematic review and IPD suggest that mass deworming
reduces maternal anaemia with moderate quality evidence. The
policy implications are that, even in high‐prevalence areas,
deworming alone is insufficient to achieve improvements in all
maternal and newborn health outcomes. These findings reinforce
that it is essential to focus on sustainable development to address
the other factors such as poor sanitation, food insecurity and
malnutrition. Mass deworming should be bundled as part of these
packages to improve range of maternal and newborn health
outcomes.
13.7 | Implications for research
There is a need to evaluate mass deworming for STH and
schistosomiasis during pregnancy in large scale programmatic
settings. Future impact evaluations should attempt to measure
various individual and environmental factors that could potentially
effect the impact of mass deworming. Future program evaluations
should also assess the long term impact of mass deworming on birth
and infant health outcomes along with the maternal health outcomes.
There is an urgent need for open data from all research studies. The
quality of evidence is rated as moderate for our findings. Further
research on maternal baseline worm intensities and birth outcomes
could change our findings.
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TABLE 13 Summary of findings table
Mass deworming for STH and Schsitosomisis during pregnancy compared to placebo
Population: Pregnant women
Setting: Low‐ middle‐ income countries of Uganda, Tanzania and Philippnes
Intervention: Mass deworming with any drug
Comparison: Placebo
Aggregate evidence IPD evidence
Outcomes
No of Participants
(Studies) RR (95% CI)
Quality of the
evidence (GRADE) RR (95% CI)
Quality of the
evidence (GRADE)
Maternal Anaemia 5216 0.94 (0.89–0.99) ⊕⊕⊕⊝ 0.77 (0.73‐0.81) ⊕⊕⊕⊝
(3 studies) Moderatea Moderatea
Maternal T.Trichiura intensity 2867 1.06 (0.87, 1.30) ⊕⊕⊕⊝ 0.69 (0.42‐1.13) ⊕⊕⊕⊝
(2 studies) Moderatea Moderatea
Maternal hookworm intensity 2867 0.39 (0.04, 3.93) ⊕⊕⊕⊝ 0.52 (0.18‐1.47) ⊕⊕⊕⊝
(2 studies) Moderatea Moderatea
LBW 2267 1.04 (0.79, 1.38) ⊕⊕⊕⊝ 0.89 (0.67, 1.18) ⊕⊕⊕⊝
(2 studies) Moderatea Moderatea
Preterm birth 2707 0.84 (0.51, 1.39) ⊕⊕⊕⊝ 0.69 (0.47, 1.03) ⊕⊕⊕⊝
(2 studies) Moderatea Moderatea
Abbreviations: CI, confidemce interval; LBW, low birthweight; RR, risk ratio; STH, soil transmitted helminths.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDowngraded for study limitations ‐ obtained only a selected sample of IPD.
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DIFFERENCE BETWEEN PROTOCOL AND REVIEW
We could not conduct the following analyses as planned due to
limited number of included studies
1. We could not conduct planned pair‐wise comaprisons for one
deworming drug versus other deworming drug or a combination
of deworming drugs.
2. We could not assess for publication bias as planned due to < 10
studies included.
3. We could not conduct the planned subgroup analysis and effect
modification.
REFERENCES
Abel, R., Rajaratnam, J., Kalaimani, A., & Kirubakaran, S. (2000). Can
iron status be improved in each of the three trimesters? A
community‐based study. European Journal of Clinical Nutrition, 54(6),
490–493.
Abrams, E. T., & Miller, E. M. (2011). The roles of the immune system in
Womenʼs reproduction: Evolutionary constraints and life history
trade‐offs. American Journal of Physical Anthropology, 146(S53),
134–154.
Ács, N., Banhidy, F., Puho, E., & Czeizel, A. E. (2005). Population‐based
case–control study of mebendazole in pregnant women for birth
outcomes. Congenital anomalies, 45(3), 85–88.
Adam, I., Elwasilae, E., & Homeida, M. (2005). Praziquantel for the
treatment of schistosomiasis mansoni during pregnancy. Annals of
Tropical Medicine & Parasitology, 99(1), 37–40.
Atukorala, T. M., de Silva, L. D., Dechering, W. H., Dassenaeike, T. S., &
Perera, R. S. (1994). Evaluation of effectiveness of iron‐folate
supplementation and anthelminthic therapy against anemia in
pregnancy—A study in the plantation sector of Sri Lanka. The
American Journal of Clinical Nutrition, 60(2), 286–292.
Austin, P. C. (2009). Balance diagnostics for comparing the distribu-
tion of baseline covariates between treatment groups in propen-
sity‐score matched samples. Statistics in Medicine, 28(25),
3083–3107.
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R.,
Brozek, J., … Norris, S. (2011). GRADE guidelines: 3. Rating the
quality of evidence. Journal of Clinical Epidemiology, 64(4),
401–406.
Barry, M. A., Simon, G. G., Mistry, N., & Hotez, P. J. (2013). Global trends in
neglected tropical disease control and elimination: Impact on child
health. Archives of Disease in Childhood, 98, 635–641.
Blackwell, A. D. (2016). Helminth infection during pregnancy: Insights
from evolutionary ecology. International Journal of Womenʼs Health, 8,
651–661.
Blackwell, A. D., Snodgrass, J. J., Madimenos, F. C., & Sugiyama, L. S.
(2010). Life history, immune function, and intestinal helminths: Trade‐
offs among immunoglobulin E, C‐reactive protein, and growth in an
Amazonian population. American Journal of Human Biology, 22(6),
836–848.
Bundy, D. A., Chan, M. S., & Savioli, L. (1995). Hookworm infection in
pregnancy. Transactions of the Royal Society of Tropical Medicine and
Hygiene, 89(5), 521–522.
Chan, M. S., Medley, G. F., Jamison, D., & Bundy, D. A. (1994). The
evaluation of potential global morbidity attributable to intestinal
nematode infections. Parasitology, 109(03), 373–387.
Christian, P., Khatry, S. K., & West, K. P. (2004). Antenatal anthelmintic
treatment, birthweight, and infant survival in rural Nepal. The Lancet,
364(9438), 981–983.
De Silva, N. R., Sirisena, J. L., Gunasekera, D. P., Ismail, M. M., & de Silva, H.
J. (1999). Effect of mebendazole therapy during pregnancy on birth
outcome. The Lancet, 353(9159), 1145–1149.
Deepti, S. S., & Nandini, L. (2015). Effects of Deworming during pregnancy
on maternal and perinatal outcomes: A randomized controlled trial.
Research Journal of Pharmaceutical Biological and Chemical Sciences,
6(1), 1521–1526.
Elliott, A. M., Kizza, M., Quigley, M. A., Ndibazza, J., Nampijja, M., Muhangi,
L., … Whitwortha, J. A. (2007). The impact of helminths on the
response to immunization and on the incidence of infection and
disease in childhood in Uganda: design of a randomized, double‐blind,
placebo‐controlled, factorial trial of deworming interventions deliv-
ered in pregnancy and early childhood [ISRCTN32849447]. Clinical
Trials, 4(1), 42–57.
Elliott, A. M., Mpairwe, H., Quigley, M. A., Nampijja, M., Muhangi, L.,
Oweka‐Onyee, J., … Whitworth, J. A. (2005). Helminth infection
during pregnancy and development of infantile eczema. Journal of the
American Medical Association, 294(16), 2028–2034.
Elliott, A. M., Namujju, P. B., Mawa, P. A., Quigley, M. A., Nampijja, M.,
Nkurunziza, P. M., …Whitworth, J. A. (2005). A randomised controlled
trial of the effects of albendazole in pregnancy on maternal responses
to mycobacterial antigens and infant responses to bacille Calmette‐
Guérin (BCG) immunisation [ISRCTN32849447]. BMC Infectious
Diseases, 5(1), 115.
Fisher, D. J., Copas, A. J., Tierney, J. F., & Parmar, M. K. B. (2011). A critical
review of methods for the assessment of patient‐level interactions in
individual participant data meta‐analysis of randomized trials, and
guidance for practitioners. Journal of Clinical Epidemiology, 64(9),
949–967.
Gyorkos, T. W., Gilbert, N. L., Larocque, R., & Casapía, M. (2011).
Trichuris and hookworm infections associated with anaemia
during pregnancy. Tropical Medicine & International Health, 16(4),
531–537.
20 of 27 | SALAM ET AL.
Gyorkos, T. W., Larocque, R., Casapia, M., & Gotuzzo, E. (2006). Lack of
risk of adverse birth outcomes after deworming in pregnant women.
The Pediatric Infectious Disease Journal, 25(9), 791–794.
Higgins, J. P. T., Altman, D. G., & Sterne, J. A. C. (2011). Chapter 8:
Assessing risk of bias in included studies, Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0. The Cochrane
Collaboration. www.cochrane‐handbook.org.
Hotez, P. J. (1983). Secretion of a proteolytic anticoagulant by
Ancylostoma hookworms. Journal of Experimental Medicine, 157(5),
1594–1603.
Kassebaum, N. J., Jasrasaria, R., Naghavi, M., Wulf, S. K., Johns, N., Lozano,
R., … Murray, C. J. L. (2014). A systematic analysis of global anemia
burden from 1990 to 2010. Blood, 123(5), 615–624.
Larocque, R., Casapia, M., Gotuzzo, E., & Gyorkos, T. W. (2005).
Relationship between intensity of soil‐transmitted helminth infections
and anemia during pregnancy. The American Journal of Tropical
Medicine and Hygiene, 73(4), 783–789.
Larocque, R., Casapia, M., Gotuzzo, E., MacLean, J. D., Soto, J. C., Rahme,
E., & Gyorkos, T. W. (2006). A double‐blind randomized controlled
trial of antenatal mebendazole to reduce low birthweight in a
hookworm‐endemic area of Peru. Tropical Medicine & International
Health, 11(10), 1485–1495.
Liabsuetrakul, T., Chaikongkeit, P., Korviwattanagarn, S., Petrueng, C., Chaiya,
S., Hanvattanakul, C., … (SSTH and MH) Working, G. (2009). Epidemiology
and the effect of treatment of soil‐transmitted helminthiasis in pregnant
women in southern Thailand. The Southeast Asian Journal of Tropical
Medicine and Public Health, 40, 211–222.
Martin, M., Blackwell, A. D., Gurven, M., & Kaplan, H. (2013). Make new
friends and keep the old? Parasite coinfection and comorbidity in
Homo sapiens, Primates, Pathogens, and Evolution (pp. 363–387.
Springer.
Millard, J. D., Muhangi, L., Sewankambo, M., Ndibazza, J., Elliott, A. M., &
Webb, E. L. (2014). Assessing the external validity of a randomized
controlled trial of anthelminthics in mothers and their children in
Entebbe, Uganda. Trials, 15(1), 310.
Tehalia, M. K. J. (2011). Impact of deworming on anaemia in pregnancy.
54th All India Congress of Obstetrics and Gynaecology, Hyderabad,
Andhra Pradesh, India.
Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M.,
… Stewart, L. A. (2015). Preferred reporting items for systematic
review and meta‐analysis protocols (PRISMA‐P) 2015 statement.
Systematic Reviews, 4(1), 1.
Mpairwe, H., Webb, E. L., Muhangi, L., Ndibazza, J., Akishule, D., Nampijja, M.,…
Elliott, A. M. (2011). Anthelminthic treatment during pregnancy is
associated with increased risk of infantile eczema: randomised‐controlled
trial results. Pediatric Allergy and Immunology, 22(3), 305–312.
Muhangi, L., Woodburn, P., Omara, M., Omoding, N., Kizito, D., Mpairwe,
H., … Elliott, A. M. (2007). Associations between mild‐to‐moderate
anaemia in pregnancy and helminth, malaria and HIV infection in
Entebbe, Uganda. Transactions of the Royal Society of Tropical Medicine
and Hygiene, 101(9), 899–907.
Nampijja, M., Apule, B., Lule, S., Akurut, H., Muhangi, L., Webb, E. L., …
Alcock, K. J. (2012). Effects of maternal worm infections and
anthelminthic treatment during pregnancy on infant motor and
neurocognitive functioning. Journal of the International Neuropsycholo-
gical Society, 18(6), 1019–1030.
Ndibazza, J., Mpairwe, H., Webb, E. L., Mawa, P. A., Nampijja, M., Muhangi,
L., … Elliott, A. M. (2012). Impact of anthelminthic treatment in
pregnancy and childhood on immunisations, infections and eczema in
childhood: A randomised controlled trial. PLoS One, 7(12), e50325.
Ndibazza, J., Muhangi, L., Akishule, D., Kiggundu, M., Ameke, C., Oweka, J.,
… Elliott, A. M. (2010). Effects of deworming during pregnancy on
maternal and perinatal outcomes in Entebbe, Uganda: A randomized
controlled trial. Clinical Infectious Diseases, 50(4), 531–540.
Ndyomugyenyi, R., Kabatereine, N., Olsen, A., & Magnussen, P. (2008a).
Efficacy of ivermectin and albendazole alone and in combination for
treatment of soil‐transmitted helminths in pregnancy and adverse
events: A randomized open label controlled intervention trial in
Masindi district, western Uganda. The American Journal of Tropical
Medicine and Hygiene, 79(6), 856–863.
Ndyomugyenyi, R., Kabatereine, N., Olsen, A., & Magnussen, P. (2008b).
Malaria and hookworm infections in relation to haemoglobin and
serum ferritin levels in pregnancy in Masindi district, western Uganda.
Transactions of the Royal Society of Tropical Medicine and Hygiene,
102(2), 130–136.
Nurdia, D. S., Sumarni, S., Suyoko, Hakim, M., &Winkvist, A. (2001). Impact of
intestinal helminth infection on anemia and iron status during pregnancy:
A community based study in Indonesia. The Southeast Asian Journal of
Tropical Medicine and Public Health, 32(1), 14–22.
Olveda, R. M., Acosta, L. P., Tallo, V., Baltazar, P. I., Lesiguez, J. L. S.,
Estanislao, G. G., … Friedman, J. F. (2016). Efficacy and safety of
praziquantel for the treatment of human schistosomiasis during
pregnancy: A phase 2, randomised, double‐blind, placebo‐controlled
trial. The Lancet Infectious Diseases, 16(2), 199–208.
Pawlowski, Z. S., Schad, G. A., & Stott, G. J. (1991). Hookworm infection
and anaemia: Approaches to prevention and control continued. World
Health Organization.
Pullan, R. L., Smith, J. L., Jasrasaria, R., & Brooker, S. J. (2014). Global
numbers of infection and disease burden of soil transmitted helminth
infections in 2010. Parasites & Vectors, 7(1), 37.
Rahman, M. M., Abe, S. K., Rahman, M. S., Kanda, M., Narita, S., Bilano, V.,
… Shibuya, K. (2016). Maternal anemia and risk of adverse birth and
health outcomes in low‐ and middle‐income countries: Systematic
review and meta‐analysis1,2. The American Journal of Clinical Nutrition,
103(2), 495–504.
Riley, R. D., Lambert, P. C., & Abo‐Zaid, G. (2010). Meta‐analysis of
individual participant data: Rationale, conduct, and reporting. BMJ,
340, c221.
Riley, R. D., Lambert, P. C., Staessen, J. A., Wang, J., Gueyffier, F., Thijs, L.,
… Boutitie, F. (2008). Meta‐analysis of continuous outcomes combin-
ing individual patient data and aggregate data. Statistics in Medicine,
27(11), 1870–1893.
Riley, R. D., & Steyerberg, E. W. (2010). Meta‐analysis of a binary outcome
using individual participant data and aggregate data. Research
Synthesis Methods, 1(1), 2–19.
Salam, R. A., Haider, B. A., Humayun, Q., & Bhutta, Z. A. (2015). Effect of
administration of antihelminthics for soil‐transmitted helminths
during pregnancy. The Cochrane Library.
Salam, R. A., Middleton, P., Makrides, M., Welch, V., Gaffey, M., Cousens,
S., & Bhutta, Z.Mass deworming for soil‐transmitted helminths
and schistosomiasis among pregnant women: A systematic review
and individual participant data meta‐analysis. The Campbell Colla-
boration.
Sifakis, S., & Pharmakides, G. (2000). Anemia in pregnancy. Annals of the
New York Academy of Sciences, 900(1), 125–136.
Stewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart,
G., … Tierney, J. F. (2015). Preferred reporting items for a systematic
review and meta‐analysis of individual participant data: The PRISMA‐
IPD statement. Journal of the American Medical Association, 313(16),
1657–1665.
Tierney, J. F., Pignon, J. P., Gueffyier, F., Clarke, M., Askie, L., Vale, C. L., …
Whiteley, W. (2015). How individual participant data meta‐analyses
have influenced trial design, conduct, and analysis. Journal of Clinical
Epidemiology, 68(11), 1325–1335.
Tierney, J. F., Vale, C., Riley, R., Smith, C. T., Stewart, L., Clarke, M., &
Rovers, M. (2015). Individual participant data (IPD) meta‐analyses of
randomised controlled trials: Guidance on their use. PLoS Medicine,
12(7), e1001855.
SALAM ET AL. | 21 of 27
Torlesse, H., & Hodges, M. (2000). Anthelminthic treatment and haemoglobin
concentrations during pregnancy. The Lancet, 356(9235), 1083.
Torlesse, H., & Hodges, M. (2001). Albendazole therapy and reduced
decline in haemoglobin concentration during pregnancy (Sierra
Leone). Transactions of the Royal Society of Tropical Medicine and
Hygiene, 95(2), 195–201.
Turner, H. C., Truscott, J. E., Hollingsworth, T. D., Bettis, C., Brooker, S. J.,
& Anderson, R. M. (2015). Cost and cost‐effectiveness of soil‐
transmitted helminth treatment programmes: Systematic review and
research needs. Parasites & Vectors, 8(1), 355.
Tweyongyere, R., Mawa, P. A., Emojong, N. O., Mpairwe, H., Jones, F. M.,
Duong, T., … Elliott, A. M. (2009). Effect of praziquantel treatment of
Schistosoma mansoni during pregnancy on intensity of infection and
antibody responses to schistosome antigens: Results of a randomised,
placebo‐controlled trial. BMC Infectious Diseases, 9(1), 32.
Tweyongyere, R., Mawa, P. A., Kihembo, M., Jones, F. M., Webb, E. L.,
Cose, S., … Elliott, A. M. (2011). Effect of praziquantel treatment of
Schistosoma mansoni during pregnancy on immune responses to
schistosome antigens among the offspring: Results of a randomised,
placebo‐controlled trial. BMC Infectious Diseases, 11(1), 234.
Tweyongyere, R., Mawa, P. A., Ngom‐wegi, S., Ndibazza, J., Duong, T.,
Vennervald, B. J., … Elliott, A. M. (2008). Effect of praziquantel
treatment during pregnancy on cytokine responses to schistosome
antigens: Results of a randomized, placebo‐controlled trial. The Journal
of infectious diseases, 198(12), 1870–1879.
Tweyongyere, R., Naniima, P., Mawa, P. A., Jones, F. M., Webb, E. L.,
Cose, S., … Elliott, A. M. (2013). Effect of maternal Schistosoma
mansoni infection and praziquantel treatment during pregnancy on
Schistosoma mansoni infection and immune responsiveness among
offspring at age five years. PLoS Neglected Tropical Diseases, 7(10),
e2501.
Urass, D., Nystrom, L., & Carlsted, A. (2011). Effectiveness of routine
antihelminthic treatment on anaemia in pregnancy in Rufiji District,
Tanzania: A cluster randomised controlled trial. East African journal of
public health, 8(3), 176–184.
Villar, M., et al. (1998). Nematode infections in pregnancy: The pyrantel
experience. American Journal of Obstetrics and Gynaecology, 178(1),
S214. Pt 2.
Walker, N., Fischer‐Walker, C., Bryce, J., Bahl, R., & Cousens, S. (2010).
Standards for CHERG reviews of intervention effects on child
survival. International Journal of Epidemiology, 39(Suppl 1), i21–i31.
Webb, E. L., Kyosiimire‐Lugemwa, J., Kizito, D., Nkurunziza, P., Lule, S.,
Muhangi, L., … Elliott, A. M. (2012). The effect of anthelmintic
treatment during pregnancy on HIV plasma viral load: Results
from a randomized, double‐blind, placebo‐controlled trial in
Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes,
60(3), 307–313.
Webb, E. L., Mawa, P. A., Ndibazza, J., Kizito, D., Namatovu, A., Kyosiimire‐
Lugemwa, J., … Elliott, A. M. (2011). Effect of single‐dose anthelmintic
treatment during pregnancy on an infantʼs response to immunisation
and on susceptibility to infectious diseases in infancy: A randomised,
double‐blind, placebo‐controlled trial. The Lancet, 377(9759),
52–62.
Welch, V, G. E., Hossain, A, Arora, P, Cousens, S, Gaffey, M, Riddle, A, …
Wells, GAMass deworming for improving health and cognition of
children in endemic helminth areas: A systematic review and
individual participant data network meta‐analysis. The Campbell
Collaboration.
Welch, V. A., et al. (2016). Deworming and adjuvant interventions for
improving the developmental health and well‐being of children in
low‐and middle‐income countries. Campbell Systematic Reviews, 12.
WHO (1994). WHO Report of the Informal Consultation on Hookworm
Infection and Anaemia in Girls and Women. (WHO/CTD/SIP/96.1).
Geneva: World Health Organization.
WHO (2005). Deworming for health and development: Report of the third
global meeting of the partners for parasite control.
WHO (2006). Preventive chemotherapy in human helminthiasis: coordinated
use of anthelminthic drugs in control interventions: A manual for health
professionals and programme managers. Geneva: World Health Orga-
nization.
WHO (2017). Guideline: Preventive chemotherapy to control soil‐transmitted
helminth infections in at‐risk population groups. Geneva: World Health
Organization.
How to cite this article: Salam R, Cousens S, Welch V, et al.
Mass deworming for soil‐transmitted helminths and
schistosomiasis among pregnant women: A systematic review
and individual participant data meta‐analysis. Campbell
Systematic Reviews. 2019;15:e1052.
https://doi.org/10.1002/cl2.1052
APPENDIX A: ADDITIONAL TABLE
See Additional Table 1.
APPENDIX B: SEARCH STRATEGY
Database: Ovid MEDLINE(R) In‐Process & Other Non‐Indexed
Citations and Ovid MEDLINE(R).
22 of 27 | SALAM ET AL.
TABLE 1 PRISMA‐IPD reporting checklists
PRISMA‐IPD Checklist of items to include when reporting a systematic review and meta‐analysis of individual participant data (IPD) PRISMA‐IPD
Section/topic
Title Item No Checklist item
Reported
on page
Title 1 Identify the report as a systematic review and meta‐analysis of
individual participant data.
1
Abstract
Structured summary 2 Provide a structured summary including as applicable: 2–4
Background: state research question and main objectives, with
information on participants, interventions, comparators and outcomes.
Methods: report eligibility criteria; data sources including dates of last
bibliographic search or elicitation, noting that IPD were sought;
methods of assessing risk of bias.
Results: provide number and type of studies and participants identified
and number (%) obtained; summary effect estimates for main outcomes
(benefits and harms) with confidence intervals and measures of statistical
heterogeneity. Describe the direction and size of summary effects in
terms meaningful to those who would put findings into practice.
Discussion: state main strengths and limitations of the evidence,
general interpretation of the results and any important implications.
Other: report primary funding source, registration number and
registry name for the systematic review and IPD meta‐analysis.
Introduction
Rationale 3 Describe the rationale for the review in the context of what is already
known.
5–9
Objectives 4 Provide an explicit statement of the questions being addressed with
reference, as applicable, to participants, interventions, comparisons,
outcomes and study design (PICOS). Include any hypotheses that
relate to particular types of participant‐level subgroups.
9
Methods
Protocol and
registration
5 Indicate if a protocol exists and where it can be accessed. If available,
provide registration information including registration number and
registry name. Provide publication details, if applicable.
9
Eligibility criteria 6 Specify inclusion and exclusion criteria including those relating to
participants, interventions, comparisons, outcomes, study design and
characteristics (e.g. years when conducted, required minimum follow‐up).
Note whether these were applied at the study or individual level i.e.
whether eligible participants were included (and ineligible participants
excluded) from a study that included a wider population than specified by
the review inclusion criteria. The rationale for criteria should be stated.
10
Identifying studies ‐
information sources
7 Describe all methods of identifying published and unpublished studies
including, as applicable: which bibliographic databases were searched
with dates of coverage; details of any hand searching including of
conference proceedings; use of study registers and agency or
company databases; contact with the original research team and
experts in the field; open adverts and surveys. Give the date of last
search or elicitation.
11
Identifying studies ‐
search
8 Present the full electronic search strategy for at least one database,
including any limits used, such that it could be repeated.
40–44
Study selection
processes
9 State the process for determining which studies were eligible for
inclusion.
10–11
Data collection
processes
10 Describe how IPD were requested, collected and managed, including
any processes for querying and confirming data with investigators. If
IPD were not sought from any eligible study, the reason for this
should be stated (for each such study).
12–13
If applicable, describe how any studies for which IPD were not
available were dealt with. This should include whether, how and what
aggregate data were sought or extracted from study reports and
publications (such as extracting data independently in duplicate) and
(Continues)
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PRISMA‐IPD Checklist of items to include when reporting a systematic review and meta‐analysis of individual participant data (IPD) PRISMA‐IPD
Section/topic
Title Item No Checklist item
Reported
on page
any processes for obtaining and confirming these data with
investigators.
Data items 11 Describe how the information and variables to be collected were
chosen. List and define all study level and participant level data that
were sought, including baseline and follow‐up information. If
applicable, describe methods of standardising or translating variables
within the IPD datasets to ensure common scales or measurements
across studies.
12–15
IPD integrity A1 Describe what aspects of IPD were subject to data checking (such as
sequence generation, data consistency and completeness, baseline
imbalance) and how this was done.
13
Risk of bias
assessment in
individual studies.
12 Describe methods used to assess risk of bias in the individual studies
and whether this was applied separately for each outcome. If
applicable, describe how findings of IPD checking were used to
inform the assessment. Report if and how risk of bias assessment was
used in any data synthesis.
12
Specification of
outcomes and effect
measures
13 State all treatment comparisons of interests. State all outcomes
addressed and define them in detail. State whether they were pre‐
specified for the review and, if applicable, whether they were
primary/main or secondary/additional outcomes. Give the principal
measures of effect (such as risk ratio, hazard ratio, difference in
means) used for each outcome.
10–11
Synthesis methods 14 Describe the meta‐analysis methods used to synthesise IPD. Specify
any statistical methods and models used. Issues should include (but
are not restricted to):
12–15
• Use of a one‐stage or two‐stage approach.
• How effect estimates were generated separately within each
study and combined across studies (where applicable).
• Specification of one‐stage models (where applicable) including
how clustering of patients within studies was accounted for.
• Use of fixed or random effects models and any other model
assumptions, such as proportional hazards.
• How (summary) survival curves were generated (where applicable).
• Methods for quantifying statistical heterogeneity (such as I2 and τ2).
• How studies providing IPD and not providing IPD were analysed
together (where applicable).
• How missing data within the IPD were dealt with (where applicable).
Exploration of
variation in effects
A2 If applicable, describe any methods used to explore variation in effects
by study or participant level characteristics (such as estimation of
interactions between effect and covariates). State all participant‐
level characteristics that were analysed as potential effect modifiers,
and whether these were pre‐specified.
14–15
Risk of bias across
studies
15 Specify any assessment of risk of bias relating to the accumulated
body of evidence, including any pertaining to not obtaining IPD for
particular studies, outcomes or other variables.
12
Additional analyses 16 Describe methods of any additional analyses, including sensitivity
analyses. State which of these were pre‐specified.
15
Results
Study selection and
IPD obtained
17 Give numbers of studies screened, assessed for eligibility, and included
in the systematic review with reasons for exclusions at each stage.
Indicate the number of studies and participants for which IPD were
sought and for which IPD were obtained. For those studies where
IPD were not available, give the numbers of studies and participants
16–1722
(Continues)
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PRISMA‐IPD Checklist of items to include when reporting a systematic review and meta‐analysis of individual participant data (IPD) PRISMA‐IPD
Section/topic
Title Item No Checklist item
Reported
on page
for which aggregate data were available. Report reasons for non‐
availability of IPD. Include a flow diagram.
Study characteristics 18 For each study, present information on key study and participant
characteristics (such as description of interventions, numbers of
participants, demographic data, unavailability of outcomes, funding
source, and if applicable duration of follow‐up). Provide (main)
citations for each study. Where applicable, also report similar study
characteristics for any studies not providing IPD.
19–20
IPD integrity A3 Report any important issues identified in checking IPD or state that
there were none.
22–24
Risk of bias within
studies
19 Present data on risk of bias assessments. If applicable, describe
whether data checking led to the up‐weighting or down‐weighting of
these assessments. Consider how any potential bias impacts on the
robustness of meta‐analysis conclusions.
21
Results of individual
studies
20 For each comparison and for each main outcome (benefit or harm), for
each individual study report the number of eligible participants for
which data were obtained and show simple summary data for each
intervention group (including, where applicable, the number of
events), effect estimates and confidence intervals. These may be
tabulated or included on a forest plot.
Results of syntheses 21 Present summary effects for each meta‐analysis undertaken, including
confidence intervals and measures of statistical heterogeneity. State
whether the analysis was pre‐specified, and report the numbers of
studies and participants and, where applicable, the number of events
on which it is based.
25–27
When exploring variation in effects due to patient or study
characteristics, present summary interaction estimates for each
characteristic examined, including confidence intervals and measures
of statistical heterogeneity. State whether the analysis was pre‐
specified. State whether any interaction is consistent across trials.
Provide a description of the direction and size of effect in terms
meaningful to those who would put findings into practice.
Risk of bias across
studies
22 Present results of any assessment of risk of bias relating to the
accumulated body of evidence, including any pertaining to the
availability and representativeness of available studies, outcomes or
other variables.
21
Additional analyses 23 Give results of any additional analyses (e.g. sensitivity analyses). If
applicable, this should also include any analyses that incorporate
aggregate data for studies that do not have IPD. If applicable,
summarise the main meta‐analysis results following the inclusion or
exclusion of studies for which IPD were not available.
27
Discussion
Summary of evidence 24 Summarise the main findings, including the strength of evidence for
each main outcome.
28–30
Strengths and
limitations
25 Discuss any important strengths and limitations of the evidence
including the benefits of access to IPD and any limitations arising
from IPD that were not available.
28–30
Conclusions 26 Provide a general interpretation of the findings in the context of other
evidence.
28–30
Implications A4 Consider relevance to key groups (such as policy makers, service providers
and service users). Consider implications for future research.
28–30
Funding
Funding 27 Describe sources of funding and other support (such as supply of IPD),
and the role in the systematic review of those providing such support.
35
A1 – A3 denote new items that are additional to standard PRISMA items. A4 has been created as a result of re‐arranging content of the standard
PRISMA statement to suit the way that systematic review IPD meta‐analyses are reported.
© Reproduced with permission of the PRISMA IPD Group, which encourages sharing and reuse for non‐commercial purposes
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1. flukes.tw.
2. platyhelminth*.tw.
3. whipworm*.tw.
4. whip worm*.tw.
5. hookworm*.tw.
6. hookworm*.tw.
7. hook worm*.tw.
8. roundworm*.tw.
9. round worm*.tw.
10. geohelminth*.tw.
11. ancylostoma*.tw.
12. Necator*.tw.
13. Ascaris.tw.
14. Ascaridida.tw.
15. Ancylostoma.tw.
16. Necator americanus.tw.
17. Trichuris.tw.
18. Trichuroidea.tw.
19. Adenophorea.tw.
20. Enoplida.tw.
21. Ascaridida.tw.
22. Platyhelminth*.tw.
23. Rotifera.tw.
24. trichuriasis.tw.
25. ascariasis.tw.
26. ancylostomiasis.tw.
27. ascarid*.tw.
28. schistosom*.tw.
29. bilharziosis.tw.
30. bilharzia*.tw.
31. exp Schistosoma/
32. or/1‐31
33. Albendazole/
34. Mebendazole/
35. exp Piperazines/
36. Levamisole/
37. exp Pyrantel/
38. Ivermectin/
39. exp Anthelmintics/
40. Ivermectin.tw.
41. Albendazole.tw.
42. Mebendazole.tw.
43. Piperazine*.tw.
44. Levamisole.tw.
45. pyrantel.tw.
46. tiabendazole.tw.
47. anthelmint*.tw.
48. Anticestodal.tw.
49. Antiplatyhelmintic.tw.
50. Anti‐platyhelmintic.tw.
51. Albendazole.tw.
52. Dichlorophen.tw.
53. Niclosamide.tw.
54. Bithionol.tw.
55. Diamfenetide.tw.
56. Nitroxinil.tw.
57. Oxyclozanide.tw.
58. Rafoxanide.tw.
59. Schistosomicid*.tw.
60. Antimony Potassium Tartrate.tw.
61. Antimony Sodium Gluconate.tw. = 62 Hycanthone.tw.
62. Lucanthone.tw.
63. Niridazole.tw.
64. Oxamniquine.tw.
65. Praziquantel/
66. Trichlorfon/
67. metrifonate.tw.
68. Artemisinins/
69. (artesunate or artemether).tw.
70. or/34‐72
71. (deworm* or de‐worm*).tw.
72. exp Anthelmintics/ or (anthelmint* or antihelmint*).tw.
73. 72 or 73
74. Pregnant Women/ or Pregnancy/ or Pregnancy Complications,
Parasitic/ pregnant wom*n .tw.
75. 32 and 71
76. 74 or 76
77. 75 and 77
Database: Embase Classic + Embase
1. whipworm*.tw.
2. whip worm*.tw.
3. hookworm*.tw.
4. hookworm*.tw.
5. hook worm*.tw.
6. roundworm*.tw.
7. round worm*.tw.
8. pinworm*.tw.
9. pin worm*.tw.
10. flukes.tw.
11. geohelminth*.tw.
12. ancylostoma.tw.
13. Necator*.tw.
14. Ascaris.tw.
15. Ascaridida.tw.
16. Ancylostoma.tw.
17. Necator americanus.tw.
18. Enterobius.tw.
19. Oxyuroidea.tw.
20. Oxyurida.tw.
21. Trichuris.tw.
22. Trichuroidea.tw.
23. Capillaria.tw.
24. Trichinella.tw.
25. Strongyloid*.tw.
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26. Oesophagostomum.tw.
27. Oesophagostomiasis.tw.
28. Acanthocephala.tw.
29. Adenophorea.tw.
30. Enoplida.tw.
31. Secernentea.tw.
32. Ascaridida.tw.
33. Rhabditida.tw.
34. Cestoda.tw.
35. Trematod*.tw.
36. Turbellaria.tw.
37. Platyhelminth*.tw.
38. Rotifera.tw.
39. trichuriasis.tw.
40. ascariasis.tw.
41. trichinellosis.tw.
42. Trichostrongyloidiasis.tw.
43. ancylostomiasis.tw.
44. enterobiasis.tw.
45. cestode*.tw.
46. trematode*.tw.
47. ascarid*.tw.
48. schistosomiasis.tw.
49. Schistosoma*.tw.
50. or/1‐49
51. Albendazole/
52. Mebendazole/
53. exp Piperazines/
54. Levamisole/
55. exp Pyrantel/
56. Ivermectin/
57. exp Anthelmintics/
58. Ivermectin.tw.
59. Albendazole.tw.
60. Mebendazole.tw.
61. Piperazine*.tw.
62. Levamisole.tw.
63. pyrantel.tw.
64. tiabendazole.tw.
65. anthelmint*.tw.
66. *Antiplatyhelmintic Agents/
67. Anticestodal.tw.
68. Antiplatyhelmintic.tw.
69. Anti‐platyhelmintic.tw.
70. Albendazole.tw.
71. Dichlorophen.tw.
72. Niclosamide.tw.
73. Bithionol.tw.
74. Diamfenetide.tw.
75. Nitroxinil.tw.
76. Oxyclozanide.tw.
77. Rafoxanide.tw.
78. Schistosomicide*.tw.
79. Antimony Potassium Tartrate.tw.
80. Antimony Sodium Gluconate.tw.
81. Hycanthone.tw.
82. Lucanthone.tw.
83. Niridazole.tw.
84. Oxamniquine.tw.
85. or/51‐84
86. (deworm* or de‐worm*).tw.
87. anthelmint*.tw.
88. anthelmintic/
89. or/86‐88
90. pregnant wom*n .tw.
91. (woman or women).tw.
92. pregnan*.tw.
93. or/90‐92
94. 50 and 85
95. 94 or 89
96. 95 and 93
APPENDIX C: EXTRACTION SHEET
Information was extracted for the following characteristics from all
the included studies:
1. Study no
2. Study ID
3. Study design
4. Country
5. Settings
6. Sample size
7. Intervention group details (Dosing, frequency, delivered by)
8. Control group details
9. Follow‐up
10. Baseline characteristics reported
11. Outcomes reported
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